All Stories

  1. Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma
  2. A Systematic Review on Combined [18F]FDG and 68Ga-SSA PET/CT in Pulmonary Carcinoid
  3. Radioimmune Imaging of α4β7 Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Disease
  4. [18F]FDG Uptake in Non-Infected Endovascular Grafts: A Retrospective Study
  5. Evidence-based medicine: reviews and meta-analysis
  6. Present status and future trends in molecular imaging of lymphocytes
  7. Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent
  8. Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update
  9. PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?
  10. [18F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab
  11. Methods for Radiolabelling Nanoparticles: PET Use (Part 2)
  12. Methods for Radiolabelling Nanoparticles: SPECT Use (Part 1)
  13. Sjögren Syndrome: New Insights in the Pathogenesis and Role of Nuclear Medicine
  14. Imaging Activated-T-Lymphocytes in the Salivary Glands of Patients with Sjögren’s Syndrome by 99mTc-Interleukin-2: Diagnostic and Therapeutic Implications
  15. Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT study
  16. Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series
  17. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation
  18. Basic statistics for nuclear medicine and radiology
  19. Gamma camera imaging of autoimmune diseases
  20. Gamma camera imaging of inflammatory bowel diseases
  21. Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR)
  22. Synthesis and Biodistribution of 99mTc-Labeled PLGA Nanoparticles by Microfluidic Technique
  23. An easy and practical guide for imaging infection/inflammation by [18F]FDG PET/CT
  24. In Vivo Imaging of Thyroid Cancer with 99mTc-TR1401 and 99mTc-TR1402: A Comparison Study in Dogs
  25. PET and SPECT Imaging of Tumor Micro-Environment: A Systematic Review of the Last 20 Years
  26. Extensive Histopathological Characterization of Inflamed Bowel in the Dextran Sulfate Sodium Mouse Model with Emphasis on Clinically Relevant Biomarkers and Targets for Drug Development
  27. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2
  28. In Vitro and In Vivo Evaluation of 99mTc-Polymyxin B for Specific Targeting of Gram-Bacteria
  29. Molecular Imaging of Autoimmune Diseases
  30. Handling of Doubtful WBC Scintigraphies in Patients with Suspected Prosthetic Joint Infections
  31. Imaging Bacteria with Radiolabelled Probes: Is It Feasible?
  32. Diabetic Foot Infections: The Diagnostic Challenges
  33. Theranostic Designed Near-Infrared Fluorescent Poly (Lactic-co-Glycolic Acid) Nanoparticles and Preliminary Studies with Functionalized VEGF-Nanoparticles
  34. Comparison of White Blood Cell Scintigraphy, FDG PET/CT and MRI in Suspected Diabetic Foot Infection: Results of a Large Retrospective Multicenter Study
  35. Imaging Modalities for the Diagnosis of Vascular Graft Infections: A Consensus Paper amongst Different Specialists
  36. RE: 99m Tc‐HMPAO‐leucocyte scintigraphy and [ 18 F]FDG‐PET/CT in infection
  37. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System
  38. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy
  39. Nuclear Medicine in Infectious Diseases
  40. Nuclear Medicine Imaging of Diabetic Foot Infections
  41. Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review
  42. Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults
  43. Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
  44. State of the Art of Natural Killer Cell Imaging: A Systematic Review
  45. Letter to the Editor regarding Falstie-Jensen et al: “Labeled white blood cell/bone marrow single-photon emission computed tomography with computed tomography fails in diagnosing chronic periprosthetic shoulder joint infection”
  46. Diagnosis of peripheral bone and prosthetic joint infections: overview on the consensus documents by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  47. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center
  48. Value of Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC in Patients with Primary Sjögren Syndrome
  49. Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology
  50. 99mTc-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients: a proof-of-concept study
  51. Labelling and Clinical Performance of Human Leukocytes Labelled with 99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent
  52. The reconstructed natural history of type 1 diabetes mellitus
  53. Correction to: Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  54. PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review
  55. Comparison of 99mTc-UBI 29-41, 99mTc-ciprofloxacin, 99mTc-ciprofloxacin dithiocarbamate and 111In-biotin for targeting experimental Staphylococcus aureus and Escherichia coli foreign-body infections: an ex-vivo study
  56. Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  57. Consensus document for the diagnosis of peripheral bone infection in adults: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  58. Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells
  59. Lower Gastrointestinal Tract Applications of PET/Computed Tomography and PET/MR Imaging
  60. Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study
  61. Leukocyte Imaging of the Diabetic Foot
  62. Infection and inflammation imaging standardization: the EANM guidelines
  63. Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline
  64. Radiolabelled nanoparticles for cancer diagnosis
  65. Recommendations on nuclear and multimodality imaging in IE and CIED infections
  66. Current Status of Molecular Imaging in Infections
  67. Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders
  68. Editorial: Molecular Imaging of Inflammation/Infection: The Future of Disease Management
  69. Molecular Imaging of Inflammatory Arthritis and Related Disorders
  70. New SPECT and PET Radiopharmaceuticals for Imaging Inflammatory Diseases: A Narrative Review
  71. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC
  72. Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study
  73. Animal models for the study of inflammatory bowel diseases: a meta-analysis on modalities for imaging inflammatory lesions
  74. Hybrid fusion images in diagnostic and therapeutic procedures
  75. Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new image interpretation criteria
  76. Hybrid imaging of musculoskeletal infections
  77. In-vivo imaging of tumor-infiltrating immune cells: implications for cancer immunotherapy
  78. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the Americ...
  79. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET
  80. Non-invasive clinical visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study.
  81. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast
  82. Radiolabeling of VEGF165 with 99mTc to evaluate VEGFR expression in tumor angiogenesis
  83. Nuclear Medicine Imaging in Pediatric Infection or Chronic Inflammatory Diseases
  84. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype
  85. OUP accepted manuscript
  86. Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis
  87. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis
  88. Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15–19, 2016; Tübingen, Germany
  89. Corrigendum
  90. Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review
  91. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren’s syndrome treated with Infliximab: a pilot study
  92. VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review)
  93. In vivo imaging of microorganisms
  94. Isolation and 111In–Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model
  95. Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors
  96. Comment on: “Diagnosis of Periprosthetic Joint Infection: The Role of Nuclear Medicine May Be Overestimated” by Claudio Diaz-Ledezma, Courtney Lamberton, Paul Lichtstein and Javad Parvizi
  97. 99mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis
  98. In Vivo Imaging of Natural Killer Cell Trafficking in Tumors
  99. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?
  100. Somatostatin Receptor Scintigraphy-Spect
  101. The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis
  102. Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
  103. Somatostatin Analogues
  104. Detection of Insulitis By Pancreatic Scintigraphy With99mTc-Labelled-IL2 and MRI in Patients With LADA (Action LADA 10)
  105. Imaging Infection and Inflammation
  106. In VivoEvaluation of TNF-Alpha in the Lungs of Patients Affected by Sarcoidosis
  107. Imaging in dermal filler diagnostics: MRI how and why
  108. 99mTc-Labeled-rhTSH Analogue (TR1401) for Imaging Poorly Differentiated Metastatic Thyroid Cancer
  109. Infection and inflammation imaging
  110. Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
  111. Comment on Aksoy et al.: FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection
  112. In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery
  113. Reply to comment by Koranda: 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections—the choice of reference tissue for a semiquantitative analysis
  114. Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study
  115. Nuclear Medicine Imaging Modalities: Bone Scintigraphy, PET-CT, SPECT-CT
  116. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
  117. A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections
  118. Diagnostic Imaging of Infections and Inflammatory Diseases
  119. Nuclear Medicine Imaging of Infections: Techniques, Acquisition Protocols and Interpretation Criteria
  120. Nuclear Medicine Imaging of Inflammatory Diseases
  121. Nuclear Medicine Imaging of Tuberculosis and Human Immunodeficiency Virus
  122. High Sensitive Thyroglobulin Assay on Thyroxine Therapy: Can it Avoid Stimulation Test in Low and High Risk Differentiated Thyroid Carcinoma Patients?
  123. Biological Therapies for Rheumatoid Arthritis: Progress to Date
  124. EANM/SNMMI Guideline for 18F-FDG Use in Inflammation and Infection
  125. Leukocyte and bacteria imaging in prosthetic joint infection
  126. About inflammation and infection
  127. The Use of18F-FDG-PET/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases
  128. Nuclear Medicine Imaging of Abdominal Infections and Inflammation
  129. Nuclear Medicine Imaging of Infections and Inflammation of Central Nervous System, Head and Neck Structures
  130. Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications
  131. Imaging of β-Cell Mass and Insulitis in Insulin-Dependent (Type 1) Diabetes Mellitus
  132. 11C-Hydroxytryptophan Uptake and Metabolism in Endocrine and Exocrine Pancreas
  133. The Role of Positron Emission Tomography in Inflammatory Bowel Disease
  134. Differences in the location and activity of intestinal Crohn’s disease lesions between adult and paediatric patients detected with MRI
  135. Added Value of 99mTc-HMPAO-Labeled Leukocyte SPECT/CT in the Characterization and Management of Patients with Infectious Endocarditis
  136. Pharmacokinetic modelling of N-(4-[18F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
  137. New frontiers of MRI in Crohn’s disease: motility imaging, diffusion-weighted imaging, perfusion MRI, MR spectroscopy, molecular imaging, and hybrid imaging (PET/MRI)
  138. Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis
  139. N-(4-18F-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes
  140. PET/MRI in infectious and inflammatory diseases: will it be a useful improvement?
  141. 99mTc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients
  142. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques
  143. Can Sequential 18F-FDG PET/CT Replace WBC Imaging in the Diabetic Foot?
  144. Time for radiobiology in the nuclear medicine community
  145. In vivo biodistribution of stem cells using molecular nuclear medicine imaging
  146. 99mTc-besilesomab (Scintimun®) in peripheral osteomyelitis: comparison with 99mTc-labelled white blood cells
  147. Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections
  148. Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide
  149. Synthesis and Evaluation of 99mTc-Labelled Monoclonal Antibody 1D09C3 for Molecular Imaging of Major Histocompatibility Complex Class II Protein Expression
  150. FDG-PET/CT in infections: the imaging method of choice?
  151. Molecular Imaging of Inflammation/Infection: Nuclear Medicine and Optical Imaging Agents and Methods
  152. Erratum to: Guidelines for the labelling of leucocytes with 99mTc-HMPAO
  153. Erratum to: Guidelines for the labelling of leucocytes with 111In-oxine
  154. Molecular imaging in atherosclerosis
  155. Guidelines for the labelling of leucocytes with 111In-oxine
  156. Guidelines for the labelling of leucocytes with 99mTc-HMPAO
  157. Imaging of cell trafficking in Crohn's disease
  158. Synthesis and Optimization of the Labeling Procedure of 99mTc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes
  159. Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies
  160. Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes
  161. Labelling of Interleukin-2 (IL-2) with 123-Iodine with Retention of Its Capacity to Bind to Activated Lymphocytes
  162. Peptide receptor therapies in neuroendocrine tumors
  163. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients
  164. Long-term survival of endodontically treated, maxillary anterior teeth restored with either tapered or parallel-sided glass-fiber posts and full-ceramic crown coverage
  165. The Contribution Of Nuclear Medicine In The Diagnosis Of Bone Metastases
  166. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor  
  167. Thyroid Cancer Imaging In Vivo by Targeting the Anti-Apoptotic Molecule Galectin-3
  168. Receptor Binding Ligands to Image Infection
  169. Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
  170. Decontamination of Root Canals with the Gallium-Aluminum-Arsenide Laser: Anin VitroStudy
  171. 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study
  172. Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck
  173. Studying the Metabolic Activity of Red Bone Marrow by Means of FDG-PET: The Need for a Standardization
  174. Can we produce an image of bacteria with radiopharmaceuticals?
  175. Prognostic Value of CD25 Expression on Lymphocytes and Tumor Cells in Squamous-Cell Carcinoma of the Head and Neck
  176. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy
  177. 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma
  178. Radiopharmaceuticals for imaging chronic lymphocytic inflammation
  179. Diagnosis of Vascular Prosthesis Infection: PET or SPECT?
  180. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma
  181. ANNEXIN V DETECTION OF LIPOPOLYSACCHARIDE-INDUCED CARDIAC APOPTOSIS
  182. Yeasts and filamentous fungi in bottled mineral water and tap water from municipal supplies
  183. Nuclear medicine imaging of diabetic foot infection: results of meta-analysis
  184. Nuclear medicine imaging of bone infections
  185. Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis
  186. Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes
  187. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques
  188. Inflammatory bowel diseases: clinical update of practical guidelines
  189. Nuclear medicine imaging of inflammatory/infective disorders of the abdomen
  190. Small animal imaging by single photon emission using pinhole and coded aperture collimation
  191. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with 99mTc‐infliximab
  192. In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy
  193. Biological evaluation of a polyvinyl siloxane impression material
  194. CT60 Single Nucleotide Polymorphisms of the Cytotoxic T-Lymphocyte–Associated Antigen-4 Gene Region is Associated with Graves' Disease in an Italian Population
  195. High Plasma Levels of Human Chromogranin a and Adrenomedullin in Patients with Pheochromocytoma
  196. The 17th International IRIST Congress Proceedings
  197. Scientific production and impact of nuclear medicine in Europe: how do we publish?
  198. 99mTc-EDDA/HYNIC-TOC in the Management of Medullary Thyroid Carcinoma
  199. Radiolabeled Annexin-V for Monitoring Treatment Response in Oncology
  200. Highlights of the Annual Congress of the European Association of Nuclear Medicine, Amsterdam 2003
  201. Radioiodinated Recombinant Human TSH: A Novel Radiopharmaceutical for Thyroid Cancer Metastases Detection
  202. The Proceedings of the 16th IRIST (International Research Group on Immunoscintigraphy and Therapy) Congress
  203. FDG-PET in infectious and inflammatory disease
  204. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract
  205. Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer
  206. False-Negative Tc-99m MIBI Scintigraphy in Histopathologically Proved Recurrent High-Grade Oligodendroglioma
  207. 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases
  208. 99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease
  209. Novel PET and SPECT radioligands for visualization of diseased regulatory pathways in breast carcinoma
  210. Reduced cumulative incidence of diabetes but not insulitis following administration of chimeric human IL-15-murine IgG2b in NOD mice
  211. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine
  212. Inflammatory Bowel Diseases: The Use of Radiolabelled Cytokines for In Vivo Evaluation of Inflammatory Activity
  213. Nuclear Medicine in the Management of Inflammatory and Infectious Diseases
  214. EDITORIAL
  215. Radiolabelled cytokines for imaging chronic inflammation
  216. Discordant Findings Between Tc-99m HMPAO Mixed Leukocytes and Tc-99m–Labeled Monoclonal Antibody Fragments (via LeukoScan) in a Patient with Pulmonary Aspergillosis
  217. Peptide Receptor Imaging
  218. Nuclear Medicine Imaging For Prediction or Early Assessment of Response to Chemotherapy in Patients Suffering From Breast Carcinoma
  219. Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging
  220. Biological Imaging for the Diagnosis of Inflammatory Conditions
  221. Assessment of Cancer-Associated Biomarkers by Positron Emission Tomography: Advances and Challenges
  222. Peptide radiopharmaceuticals for diagnosis and therapy
  223. Erratum to: Peptide radiopharmaceuticals for diagnosis and therapy
  224. Editorial
  225. THE DEVELOPING ROLE OF CYTOKINES FOR IMAGING INFLAMMATION AND INFECTION
  226. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet
  227. Identification and Characterization of a Ligand-independent Oligomerization Domain in the Extracellular Region of the CD95 Death Receptor
  228. CTLA-4 and HLA gene susceptibility to thyroidassociated orbitopathy
  229. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma
  230. Characterization of a New Form of Inherited Hypercholesterolemia
  231. In vivo imaging of insulitis in autoimmune diabetes
  232. Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes
  233. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse
  234. A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime
  235. CD95 ligand expression on alpha cells: protection or killing?
  236. Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes
  237. CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice
  238. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele
  239. 4.P.288 The metabolic basis of a new form of recessive hypercholesterolemia: The “FH-like” hypercholesterolemia
  240. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)
  241. The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the In vivo detection of mononuclear cell infiltrates in immune-mediated diseases
  242. Metformin Does Not Alter Diabetes Incidence in the NOD Mouse
  243. Radiopharmaceuticals for the study of 4 inflammatory processes
  244. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes
  245. Standardizing Experiments with NOD Mice
  246. Effect of metformin on liver insulin metabolism and regional blood flow
  247. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study)
  248. Usefulness of scintigraphy using 99mTc-EMPAO labelled granulocytes (PMN) as early indicator of postoperative asymptomatic recurrence in Crohn's disease (CD)
  249. New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123I-labelled interleukin 2
  250. Nicotinamide vs Steroids in Recent-Onset Diabetes: Impact on 3-Cell Function
  251. Histological study of pancreatic beta-cell loss in relation to the insulitis process in the non-obese diabetic mouse
  252. Randomized Trial Comparing Nicotinamide and Nicotinamide Plus Cyclosporin in Recent Onset Insulin-dependent Diabetes (IMDIAB 1)
  253. A simple method for the evaluation of receptor binding capacity of modified cytokines
  254. The effect of a heparin analogue, ITF-5005, on diabetes incidence and insulitis in the non-obese diabetic mouse
  255. Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse
  256. NOD mouse colonies around the world- recent facts and figures
  257. What future for therapeutic prevention of Type I (insulin-dependent) diabetes mellitus?
  258. A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies
  259. Immunotherapy with Ciamexon in the Non Obese Diabetic (NOD) Mouse
  260. Clinical remission in patients with IDDM and family history of NIDDM
  261. Raised temperature reduces the incidence of diabetes in the NOD mouse
  262. Lessons from the NOD mouse for the pathogenesis and immunotherapy of human Type 1 (insulin-dependent) diabetes mellitus
  263. The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice
  264. In vivo kinetics of 1231-labelled insulin
  265. Imaging of leukocytic infiltration in human cerebral infarcts.
  266. Labelling of lymphocytes with indium 111 oxine: Effect on cell surface phenotype and antibody-dependent cellular cytotoxicity